# Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Source: https://onco.cc/trials/nct05316155/  
OnCo record `nct05316155` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Erdafitinib in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer is a phase 1/2 interventional study registered as NCT05316155 by Janssen Research & Development, LLC, with 235 participants enrolled, started 2022-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: Erdafitinib Intravesical Delivery System.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05316155
- Phase: 1/2
- Setting: Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 235

## Sources

- ClinicalTrials.gov NCT05316155: https://clinicaltrials.gov/study/NCT05316155

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Erdafitinib](https://onco.cc/drugs/erdafitinib/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05316155.json